Related Experiment Video
Updated: Jul 16, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
The PEACE-24 study: Tezepelumab improves exercise tolerance and symptoms control in severe asthma
Benedetta Bondi1, Fulvio Braido1, Alessandro Pilo2
1Respiratory and Allergy Clinic, IRCCS Azienda Ospedaliera Metropolitana, Genoa, Italy; Department of Internal Medicine (DIMI), University of Genoa, Genoa, 16132, Italy.
Respiratory Medicine
|July 14, 2026
Summary
Tezepelumab significantly improved exercise tolerance in severe asthma patients, as measured by the six-minute walking test (6MWT). This finding suggests exercise capacity is a treatable trait in severe asthma management.
Area of Science:
- Pulmonology
- Clinical Medicine
- Pharmacology
Background:
- Tezepelumab effectively controls severe asthma and reduces exacerbations.
- It mitigates bronchial hyperresponsiveness and mucus hypersecretion, improving respiratory function.
- Tezepelumab's anti-inflammatory effects suggest potential for enhanced exercise tolerance.
Purpose of the Study:
- To evaluate Tezepelumab's impact on exercise tolerance in severe asthma patients.
- To assess changes in exercise capacity using the six-minute walking test (6MWT).
Main Methods:
- A study included severe asthma patients treated with Tezepelumab.
- Assessments at baseline and 24 weeks included spirometry, exhaled nitric oxide, questionnaires (ACT, AQLQ, SNOT22, RAPP), and 6MWT.
- Paired t-tests and Spearman's correlation analyzed pre- and post-treatment data.
Main Results:
- Patients showed significant improvement in 6MWT distance (409m to 478m, p=0.031) and % predicted (73% to 82%, p=0.034).
- Dyspnea (Borg scale) decreased (3.55 to 1.47, p=0.002), and AQLQ physical exercise domain scores improved (4.24 to 5.80, p=0.01).
- Improved FEV1 correlated positively with increased walking distance (ρ=0.658, p=0.028).
Conclusions:
- Tezepelumab treatment significantly increases exercise tolerance in severe asthma.
- Exercise capacity emerges as a potentially treatable trait in managing severe asthma.
- These findings support Tezepelumab's role in improving quality of life for severe asthma patients.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:24Asthma-III: Symptoms and Complications
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
01:13Asthma III: Clinical Manifestations
Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...